Nanosensors target enzymes to monitor and study cancer
By analyzing enzyme activity at the organism, tissue, and cellular scales, new sensors could provide new tools to clinicians and cancer researchers.
By analyzing enzyme activity at the organism, tissue, and cellular scales, new sensors could provide new tools to clinicians and cancer researchers.
Researchers have developed a technique that could help fine-tune the production of monoclonal antibodies and other useful proteins.
Using biological, chemical, and engineering tools, she has developed strategies to attack molecules once thought to be “undruggable.”
Now in its second year, the Rise program targets exceptional teenage scholars from around the world for their potential as future change-makers.
Study finds the protein MTCH2 is responsible for shuttling various other proteins into the membrane of mitochondria. The finding could have implications for cancer treatments and MTCH2-linked conditions.
Hynes and two other scientists will share the prize for their discoveries of proteins critical for cellular adhesion.
As an MSRP-Bio student in the Vander Heiden lab, Alejandra Rosario helped to reveal how cancer cells maintain access to materials they need to grow.
A new model that maps developmental pathways to tumor cells may unlock the identity of cancers of unknown primary.
The findings of a large-scale screen could help researchers design nanoparticles that target specific types of cancer.
With particles that release their payloads at different times, one injection could provide multiple vaccine doses.
Insight into the way the EGF receptor sends signals into cells could help researchers design new cancer drugs that target this protein.
Piction Health, founded by Susan Conover SM ’15, uses machine learning to help physicians identify and manage skin disease.
The system rapidly scans the genome of cancer cells, could help researchers find targets for new drugs.
Tested using a new brain tissue model, the particles may be able to deliver chemotherapy drugs for glioblastoma.
MIT and Mass General Brigham researchers and physicians connect in person to bring AI into mainstream health care.